Samantha DiGrande

AAM's Christine Simmon on Biosimilars Council Initiatives and Educating Around Interchangeability

February 16, 2019

After the Association for Accessible Medicines’ (AAM’s) Access! 2019 annual meeting came to a close last week, The Center for Biosimilars® spoke with Christine Simmon, senior vice president of policy and strategic alliances, AAM, and executive director, AAM’s Biosimilars Council, to get her take on some of the outcomes of the meeting.

IQVIA Data Show ANDA Approvals on the Rise, Biosimilars Fighting for Market Share

February 11, 2019

During the Association for Accessible Medicines’ Access! 2019 meeting, Doug Long, vice president of industry relations at IQVIA, gave an update about what trends are being identified in the generic and biosimilars markets across the globe.

Stakeholders Debate the Merits of Drug Pricing Legislation

February 07, 2019

Addressing the rising cost of drugs in the United States has become a problem that many entities and stakeholders are hoping to solve. From the federal government down to the state level, everyone seems to be taking the problem into their own hands.

According to Azar, "Those Against Biosimilars Are Simply on the Wrong Side of History"

February 07, 2019

HHS Secretary Alex Azar offered a view of hope and optimism for the future of the American healthcare market in his remarks delivered as the closing keynote address at the Association for Accessible Medicine’s Access! 2019 meeting.